The DOI matches its Crossref record.
177: Impact of elexacaftor/tezacaftor/ivacaftor therapy use on pulmonary exacerbation rates during the COVID-19 pandemic
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a smaller study performed during the pandemic period observed reductions in PEx rates that were significantly more pronounced in the population treated with ELX/TEZ/IVA compared to those who were not (80.2%reduction vs. 29.5% reduction, respectively) [23] .”
From Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study (2023) · cites this paper as [23]
Citations
Cited by
Sorted by citations
Bower, J. K., Volkova, N., Ahluwalia, N., Sahota, G., Xuan, F., Chin, A., Weinstock, T. G., Ostrenga, J., & Elbert, A. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.03.002 · Cited by 140
Metadata
- Authors
- Menten, E., Saroya, T., DiMango, E., & Keating, C.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 20
- Pages
- S87-S88
- ISSN
- 1569-1993
- Cited by
- 3
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 177: Impact of elexacaftor/tezacaftor/ivacaftor therapy use on pulmonary exacerbation rates during the COVID-19 pandemic. https://app.cochat.ai/papers/10.1016/s1569-1993(21)01602-7
- The paper
- Menten, E., Saroya, T., DiMango, E., & Keating, C. (2021). 177: Impact of elexacaftor/tezacaftor/ivacaftor therapy use on pulmonary exacerbation rates during the COVID-19 pandemic. Journal of Cystic Fibrosis. https://doi.org/10.1016/s1569-1993(21)01602-7
